Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.65 |
| ▸ | HTR1D | P28221 | 7/20 | 0.56 |
| ▸ | HTR1B | P28222 | 7/20 | 0.56 |
| ▸ | MPO | P05164 | 3/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.48 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27836173 | 0.90 | MPO (0.62) | HTR2AHTR1DHTR1BMPOHTR2C | |
| SCHEMBL26508293 | 0.89 | HTR2A (0.70) | HTR2AHTR1DHTR1BMPOBRD4 | |
| SCHEMBL27816670 | 0.88 | HTR2A (0.56) | HTR2AHTR1DHTR1BMPOALKBH5 | |
| SCHEMBL8506914 | 0.86 | HTR1D (0.71) | HTR2AHTR1DHTR1BMPOBRD4 | |
| SCHEMBL26508382 | 0.83 | HTR2A (0.65) | HTR2AHTR1DHTR1BMPOHTR2C | |
| SCHEMBL26508393 | 0.83 | MPO (0.75) | HTR2AHTR1DHTR1BMPO | |
| SCHEMBL26508366 | 0.83 | HTR2A (0.65) | HTR2AHTR1DHTR1BMPOBRD4 | |
| SCHEMBL26508384 | 0.83 | HTR2A (0.65) | HTR2AHTR1DHTR1BMPOHTR2C | |
| SCHEMBL26508360 | 0.83 | HTR2A (0.65) | HTR2AHTR1DHTR1BMPOHTR2C | |
| SCHEMBL26508329 | 0.83 | HTR2A (0.65) | HTR2AHTR1DHTR1BMPOHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR1D 15/4885HTR1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.